25
Mar, 2016
FDA likely to approve expanded indication of Abiomed’s Impella heart pump: SEC filing
Abiomed ($ABMD) revealed in an SEC filing that the FDA has agreed to forgo an advisory panel meeting to discuss an expanded indication for its Impella 2.5, Impella CP, Impella 5.0 and Impella LD heart pumps, meaning permission to…
READ MORE